A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas, as well as develops a data analytics and artificial intelligence platform to integrate diverse data sets into actionable insights that support precision oncology, therapeutic development, and clinical decision-making. The company was formerly known as Plus Therapeutics, Inc. and changed its name to Cerenome, Inc. in August 2026. Cerenome, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Financial Summary
| Share Statistics | CNSY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $20.6 | $286.3 | 10% |
|
| Shares Out (Mil) | 6.6 | 54.2 | 16% |
|
| Institutional Ownership | 91.0% | 92.8% | 59% |
|
| Float (Mil) | 6.5 | 39.7 | 14% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 88 | 534 | 33% |
|
| Price Change (52-week) |
(77.1%) | 58.7% | 7% |
|
| Growth | CNSY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 76.9% | 13.6% | 98% |
|
| Net Income (5yr) | (22.3%) | (10.1%) | 18% |
|
| EPS (5yr) | 59.9% | 16.0% | 96 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 14.9% | (15.6%) | 72% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 1 | 4 | |
| Current EPS | ($0.893) | ($5.000) | ($2.395) | |
| Month Ago EPS | ($0.860) | ($3.923) | ($2.395) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.850) | ($3.870) | ($2.365) | |
| Year/Year Chg | (14.5%) | (31.0%) | (96.0%) | |
| Financials | CNSY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $37 | 6% |
|
| Net Income (TTM) (Mil) | ($12) | ($43) | 28% |
|
| EPS (TTM) | ($2.578) | ($1.400) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($21) | ($31) | 15% |
|
| Net Cash Flow (TTM) (Mil) | ($7) | $2 | 32% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $11 | $160 | 8% |
|
| Valuation | CNSY | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.72 | 2.77 | 45% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | CNSY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (99.4%) | 64.2% | 2% |
|
| Net Margin | (620.7%) | (75.9%) | 1% |
|
| ROA | (74.6%) | (47.3%) | 8% |
|
| ROE | 204.3% | (55.0%) | 98% |
|
| Liabilities to Assets | 39.9% | 29.6% | 30% |
|
| F-Score | 2 | 2 | 7% |
|
Cerenome, Inc. did not pass any screens on 8/20/2026.
